{"gene":"BCL9","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2002,"finding":"BCL9 (Drosophila ortholog Legless/Lgs) physically links Pygopus (Pygo) to nuclear β-catenin, thereby recruiting Pygo to the β-catenin–TCF complex and enabling Wnt transcriptional activation. Genetic and molecular (co-IP, epistasis) evidence established this adaptor function.","method":"Genetic epistasis in Drosophila, co-immunoprecipitation, domain mapping","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic epistasis combined with molecular co-IP in founding paper; independently replicated across multiple subsequent labs","pmids":["11955446"],"is_preprint":false},{"year":2006,"finding":"Crystal structure of a β-catenin/BCL9/Tcf-4 triple complex at 2.6 Å resolution revealed that BCL9's β-catenin-binding domain (CBD) forms an α-helix that contacts the first armadillo repeat of β-catenin — a site distinct from cadherin/α-catenin binding. Mutation of this armadillo repeat abolished BCL9 binding without disrupting cadherin interactions.","method":"X-ray crystallography (2.6 Å), structure-guided mutagenesis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution structure with functional mutagenesis validating the binding interface","pmids":["17052462"],"is_preprint":false},{"year":2008,"finding":"The BCL9/Legless HD1 domain forms a ternary complex with the Pygo PHD finger to bind specifically to histone H3 methylated at lysine 4 (H3K4me2). HD1 association is required for efficient H3K4me binding, and this histone-decoding function is necessary for Wnt signaling outputs in Drosophila rescue experiments.","method":"Crystal structures of PHD–HD1–H3K4me peptide ternary complexes; ITC binding assays; Drosophila rescue genetics","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple crystal structures plus functional rescue in vivo; single lab but orthogonal methods","pmids":["18498752"],"is_preprint":false},{"year":2004,"finding":"BCL9-2 (B9L) binding to β-catenin modulates the switch between β-catenin's adhesive and transcriptional functions. Phosphorylation of Tyr142 of β-catenin favors BCL9-2 binding and precludes α-catenin interaction, thereby promoting nuclear (transcriptional) over membrane (adhesive) β-catenin function. RNAi of BCL9-2 in carcinoma cells induces epithelial phenotype and relocates β-catenin from nucleus to membrane.","method":"RNAi knockdown, co-immunoprecipitation, phosphorylation site mutagenesis, zebrafish epistasis","journal":"Genes & development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (RNAi, Co-IP, mutagenesis, in vivo zebrafish); single lab; Tyr142 mechanism later questioned by Hoffmans 2006","pmids":["15371335"],"is_preprint":false},{"year":2006,"finding":"BCL9-2 can functionally replace Drosophila Legless (BCL9) in vivo and in cultured cells, and this rescue requires the ability of BCL9-2 to bind Pygo; the Tyr142 phosphorylation of β-catenin was found not to be important for BCL9-2 recruitment or transcriptional activity in multiple assays.","method":"Drosophila in vivo rescue assays, mammalian cell transcriptional reporter assays, co-immunoprecipitation","journal":"Mechanisms of development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro assays across two systems; single lab; directly contradicts Brembeck 2004 on Tyr142","pmids":["17113272"],"is_preprint":false},{"year":2008,"finding":"BCL9 is required for efficient β-catenin-mediated transcription in Wnt-stimulated HEK293 cells and SW480 colorectal cancer cells (APC-mutant). BCL9 function depends on both its β-catenin-binding domain and an unknown C-terminal ligand. BCL9 and B9L/BCL9-2 are Wnt-inducible genes, indicating a positive feedback loop.","method":"RNAi knockdown, dominant-negative overexpression, TCF/LEF reporter assays in human cell lines","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — RNAi plus dominant-negative approach; single lab; two cell-line contexts","pmids":["18627596"],"is_preprint":false},{"year":2008,"finding":"BCL9 contains a C-terminal transcriptional activation domain that functionally synergizes with β-catenin's C-terminal transactivation domain in lymphoid cells, and this activity is partially Pygopus-independent. The β-catenin transactivation domain associates with histone acetyltransferases CBP/p300 and TRRAP/GCN5.","method":"Luciferase reporter assays, deletion/mutation analysis, co-immunoprecipitation in lymphoid and non-lymphoid cell lines","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — domain deletion analysis plus Co-IP in multiple cell types; single lab","pmids":["18347063"],"is_preprint":false},{"year":2009,"finding":"BCL9 enhances β-catenin-mediated transcriptional activity and promotes proliferation, migration, invasion, and metastasis of tumor cells. BCL9 knockdown in xenograft models reduced tumor load, metastasis, and angiogenesis, accompanied by downregulation of c-Myc, cyclin D1, CD44, and VEGF.","method":"RNAi knockdown, overexpression, in vitro migration/invasion assays, xenograft mouse models","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo functional studies with defined molecular readouts; single lab","pmids":["19738061"],"is_preprint":false},{"year":2009,"finding":"BCL9 is required for Wnt/β-catenin cascade activation in adult myogenic progenitors; loss of BCL9/BCL9-2 (via Cre-lox deletion or RNAi) abrogates nuclear β-catenin localization and TCF/LEF-mediated transcription normally observed upon Wnt stimulation, and impairs myogenic differentiation and muscle regeneration.","method":"Cre-lox conditional knockout in mouse myogenic lineage, RNAi in vitro, β-catenin localization by immunofluorescence, TCF/LEF reporter assays","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo conditional knockout replicated in vitro with RNAi; defined cellular phenotype with molecular readout","pmids":["19699733"],"is_preprint":false},{"year":2010,"finding":"Conditional ablation of Bcl9/Bcl9l in mouse intestinal epithelium decreases intestinal stem cell marker expression and impairs colon regeneration. In Wnt-driven adenocarcinomas, loss of Bcl9/Bcl9l abrogates EMT and stem-cell-like transcriptional programs, demonstrating that BCL9/BCL9l are specifically required for a Wnt-dependent stem cell and EMT gene expression program.","method":"Conditional knockout mouse genetics (intestine-specific Cre), transcriptional profiling, histology","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO in vivo with defined molecular and phenotypic readouts; replicated in tumor context","pmids":["20682801"],"is_preprint":false},{"year":2012,"finding":"A stabilized α-helix of BCL9 (SAH-BCL9) that mimics the BCL9 HD2 domain binds β-catenin, dissociates native β-catenin/BCL9 complexes, and selectively suppresses Wnt transcription. This peptide inhibitor suppresses tumor growth, angiogenesis, invasion, and metastasis in xenograft models, mechanistically validating BCL9 HD2-mediated direct binding to β-catenin as essential for oncogenic Wnt signaling.","method":"Stabilized α-helix peptide design, co-immunoprecipitation disruption assays, luciferase reporter, xenograft mouse models","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — peptide reconstitution of binding interface with functional inhibition in vitro and in vivo; mechanistic mutagenesis supported by prior crystal structure","pmids":["22914623"],"is_preprint":false},{"year":2013,"finding":"LATS2 inhibits oncogenic Wnt/β-catenin transcription by directly interacting with β-catenin and disrupting the β-catenin/BCL9 interaction, thereby blocking BCL9 recruitment to Wnt target gene promoters. This function is independent of LATS2 kinase activity.","method":"Co-immunoprecipitation, ChIP on Wnt target gene promoters, reporter assays, kinase-dead mutant analysis","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and ChIP; kinase-independent mechanism demonstrated; single lab","pmids":["24360964"],"is_preprint":false},{"year":2017,"finding":"BCL9 and B9L (BCL9L) are constitutive components of the Wnt enhanceosome. CRISPR/Cas9 engineering and BioID proximity labeling showed that the C-terminus of BCL9/B9L (downstream of the adaptor elements) is required for Wnt responses. The BCL9/B9L C-terminus binds the Groucho/TLE co-repressor and also binds the Chip/LDB1-SSDP enhanceosome core complex via a conserved element. Upon Wnt-dependent β-catenin docking, a rearrangement apposes the BCL9/B9L C-terminus to TCF.","method":"CRISPR/Cas9 genome engineering, BioID proximity labeling, co-immunoprecipitation, domain deletion analysis in Drosophila and human cells","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — CRISPR engineering combined with proximity labeling and Co-IP across two organisms; multiple orthogonal methods in one study","pmids":["28296634"],"is_preprint":false},{"year":2017,"finding":"HIF-1α transcriptionally induces BCL9 expression in human colorectal cancer cells via two functional hypoxia-responsive elements (HRE-B and HRE-C) in the BCL9 promoter. HIF-2α does not activate BCL9. This establishes a mechanistic link between hypoxia signaling and Wnt/β-catenin coactivator expression.","method":"BCL9 promoter luciferase reporter assays with HRE mutations, HIF-1α/2α overexpression and siRNA knockdown, ChIP","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter plus mutagenesis of HREs and siRNA; single lab, multiple orthogonal methods","pmids":["27121066"],"is_preprint":false},{"year":2018,"finding":"CDK1 phosphorylates BCL9 at Thr172 (N-terminal) during mitosis. This phosphorylation prevents clathrin-mediated degradation of LRP6 signalosome components by BCL9 interacting with clathrin and Wnt destruction complex components, thereby sustaining mitotic Wnt signaling and promoting precise cell division.","method":"Mitotic interactome analysis (MS), co-immunoprecipitation, phospho-site mutagenesis (T172A), cell division assays","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-defined interactome with Co-IP validation and phospho-mutant functional analysis; single lab","pmids":["30217955"],"is_preprint":false},{"year":2018,"finding":"In zebrafish and mouse, disrupting the β-catenin–BCL9–Pygo complex by combined Bcl9/Pygo mutations causes congenital heart defects with broadly maintained canonical Wnt responses in other tissues, identifying BCL9 and Pygo as selective β-catenin cofactors for a subset of Wnt-dependent cardiac developmental programs.","method":"Zebrafish and mouse genetics (combined Bcl9/Pygo mutants), gene expression analysis of cardiac regulators","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — dual-organism genetic analysis with defined tissue-specific phenotype; convergent results across zebrafish and mouse","pmids":["30366904"],"is_preprint":false},{"year":2019,"finding":"Intestinal deletion of Bcl9/Bcl9l suppresses Wnt pathway deregulation following APC loss, reduces intestinal tumour growth (especially colonic), and completely abrogates β-catenin-driven intestinal and hepatocellular transformation. Loss of BCL9/9l also synergizes with Pygo loss to shift gene expression from stem-cell-like to Notch-regulated secretory differentiation in Apc-mutant adenomas.","method":"Conditional knockout mouse genetics (ApcMin and Apc1322T models), genetic rescue/synergy with Pygo deletion, gene expression profiling","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple in vivo genetic models with mechanistic molecular readouts; two independent Nature Communications papers with convergent findings","pmids":["30760720","30760710"],"is_preprint":false},{"year":2020,"finding":"BCL9 has a β-catenin-independent function: in response to calcium transients or cellular stress, BCL9 is recruited to interchromosomal regions where it stabilizes mRNAs of calcium signaling and neural-associated genes by interacting with paraspeckle proteins, thereby sustaining neurotransmitter-dependent communication among colorectal cancer cells.","method":"Co-immunoprecipitation with paraspeckle proteins, RNA-IP, live-cell imaging of calcium transients, siRNA knockdown","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — novel β-catenin-independent mechanism supported by Co-IP and RNA-IP; single lab","pmids":["31911584"],"is_preprint":false},{"year":2023,"finding":"Crystal structure of a ternary complex comprising the N-terminus of human Pygo2, LDB1, and SSBP2 revealed that BCL9-Pygo assembles with the LDB-SSBP core complex via a conserved N-terminal NPF motif of Pygo2. A single LDB1-SSBP2 complex simultaneously binds two Pygo2 molecules through their NPF motifs, which dock into a deep groove between LDB1 and SSBP2. Loss of LDB or Pygo in human cell lines impairs Wnt/β-catenin-dependent transcription.","method":"X-ray crystallography, co-immunoprecipitation, CRISPR/Cas9 human cell line knockouts with reporter assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution crystal structure with functional validation by CRISPR KO; multiple orthogonal methods","pmids":["37349336"],"is_preprint":false},{"year":2017,"finding":"SOX7 inhibits oncogenic β-catenin-mediated transcription by competing with BCL9 to bind β-catenin, thereby disrupting the β-catenin/BCL9 interaction.","method":"Co-immunoprecipitation, TCF/LEF luciferase reporter assays, competitive binding analysis","journal":"DNA and cell biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP and reporter assay; single lab; limited mechanistic follow-up","pmids":["29271667"],"is_preprint":false},{"year":2024,"finding":"BCL9 interacts with Nrf2; BCL9 knockdown decreases Nrf2 expression and affects Nrf2 downstream target genes, inducing ferroptosis in thyroid carcinoma cells. Co-IP confirmed the BCL9–Nrf2 physical interaction.","method":"Co-immunoprecipitation, siRNA knockdown, ferroptosis assays, xenograft mouse model","journal":"Molecular carcinogenesis","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP from one lab; novel interaction not independently replicated","pmids":["39291848"],"is_preprint":false},{"year":2020,"finding":"BCL9 forms a complex with phosphoserine-727 STAT3 and non-STAT3 transcription factors on chromatin enhancers in DCIS cells. ChIP-exo showed BCL9-pS727-STAT3 co-occupancy at enhancers driving transcription of integrin β3 and MMP16, which mediate DCIS invasive progression.","method":"ChIP-exo, RNA sequencing, siRNA knockdown of BCL9 in PDX DCIS MIND model","journal":"NPJ breast cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-exo provides genome-wide co-occupancy evidence; functional link via target gene knockdown; single lab","pmids":["32352029"],"is_preprint":false}],"current_model":"BCL9 functions as an obligate adaptor protein within the Wnt enhanceosome: it physically bridges Pygopus (via its HD1 domain binding the Pygo PHD finger to read H3K4me2) to nuclear β-catenin (via its HD2 α-helical domain contacting armadillo repeat 1), assembles constitutively with the LDB1-SSBP core complex through Pygo's NPF motif, and recruits co-repressor Groucho/TLE and co-activators (CBP/p300, TRRAP/GCN5) through its C-terminus, thereby licensing context-specific Wnt transcriptional activation of TCF/LEF target genes; additionally, BCL9 has β-catenin-independent roles including stabilization of calcium-signaling mRNAs via paraspeckle proteins, regulation of mitotic Wnt signaling through CDK1-mediated Thr172 phosphorylation that inhibits clathrin-mediated LRP6 degradation, and interaction with Nrf2 to modulate ferroptosis susceptibility."},"narrative":{"mechanistic_narrative":"BCL9 is an obligate adaptor protein of the nuclear Wnt/β-catenin transcriptional machinery, physically linking the chromatin reader Pygopus to nuclear β-catenin and thereby licensing activation of TCF/LEF target genes [PMID:11955446]. Structurally, its HD2 domain forms an α-helix that contacts the first armadillo repeat of β-catenin—a site distinct from the cadherin/α-catenin interface—while its HD1 domain assembles with the Pygo PHD finger to decode H3K4-methylated histones, an interaction required for Wnt output [PMID:17052462, PMID:18498752]. Within the Wnt enhanceosome, the BCL9/B9L C-terminus binds the Groucho/TLE co-repressor and the LDB1–SSBP enhanceosome core, with β-catenin docking triggering a rearrangement that apposes the C-terminus to TCF; the Pygo NPF motif anchors BCL9-Pygo to a single LDB1-SSBP2 complex that binds two Pygo molecules [PMID:28296634, PMID:37349336]. BCL9 promotes β-catenin-driven transcription of oncogenic and stem-cell/EMT programs (c-Myc, cyclin D1, CD44, VEGF), and conditional ablation in mouse intestine and liver abrogates β-catenin-driven transformation and EMT while sparing broader Wnt responses, defining BCL9 as a context-selective β-catenin cofactor [PMID:19738061, PMID:20682801, PMID:30760720, PMID:30760710]. This selectivity extends to development, where BCL9/Pygo are required for a subset of cardiac and myogenic Wnt programs [PMID:19699733, PMID:30366904]. BCL9 expression is induced by HIF-1α through promoter hypoxia-responsive elements, and disrupting the β-catenin–BCL9 interface with a stabilized HD2 α-helix peptide suppresses tumor growth, validating the interaction as a therapeutic target [PMID:22914623, PMID:27121066]. Beyond canonical Wnt signaling, BCL9 stabilizes calcium-signaling and neural mRNAs via paraspeckle proteins independently of β-catenin [PMID:31911584], and CDK1 phosphorylates BCL9 at Thr172 during mitosis to sustain mitotic Wnt signaling by limiting clathrin-mediated LRP6 degradation [PMID:30217955].","teleology":[{"year":2002,"claim":"Established the founding role of BCL9 as the molecular adaptor that recruits Pygopus to the β-catenin–TCF complex, answering how Pygo is brought into Wnt transcriptional control.","evidence":"Genetic epistasis in Drosophila (Legless), co-immunoprecipitation and domain mapping","pmids":["11955446"],"confidence":"High","gaps":["Atomic basis of the β-catenin and Pygo contacts not yet resolved","Identity of additional C-terminal effectors unknown"]},{"year":2006,"claim":"Defined the atomic interface by which BCL9 binds β-catenin, showing the HD2 α-helix engages armadillo repeat 1 at a site distinct from cadherin/α-catenin, explaining how transcriptional and adhesive β-catenin pools are separated.","evidence":"X-ray crystallography (2.6 Å) of β-catenin/BCL9/Tcf-4 with structure-guided mutagenesis","pmids":["17052462"],"confidence":"High","gaps":["Did not address how the interaction is regulated in vivo","Affinity/competition with other armadillo-repeat ligands not quantified"]},{"year":2008,"claim":"Showed that the BCL9 HD1 domain enables Pygo to read H3K4me2, converting the adaptor into part of a histone-decoding module required for Wnt output.","evidence":"PHD–HD1–H3K4me peptide crystal structures, ITC, Drosophila rescue genetics","pmids":["18498752"],"confidence":"High","gaps":["Genomic targets of the histone-reading function not mapped","Mechanistic coupling between H3K4me reading and transcriptional activation unresolved"]},{"year":2004,"claim":"Tested how β-catenin's adhesive-versus-transcriptional switch is controlled, proposing that Tyr142 phosphorylation favors BCL9-2 over α-catenin binding to drive nuclear function.","evidence":"RNAi, Co-IP, phospho-site mutagenesis, zebrafish epistasis in carcinoma cells","pmids":["15371335"],"confidence":"Medium","gaps":["The Tyr142 mechanism was contradicted by subsequent work (idx 4)","Single-lab finding"]},{"year":2006,"claim":"Demonstrated functional interchangeability of BCL9-2 with Drosophila Legless and showed Pygo binding is essential, while disputing the proposed importance of β-catenin Tyr142 phosphorylation.","evidence":"Drosophila rescue, mammalian reporter assays, Co-IP","pmids":["17113272"],"confidence":"Medium","gaps":["Conflict with idx 3 on Tyr142 not reconciled within this study","Single lab"]},{"year":2008,"claim":"Established that BCL9 is required for β-catenin-mediated transcription in human Wnt-responsive and APC-mutant colorectal cells and identified an essential but uncharacterized C-terminal ligand, plus a Wnt-inducible feedback loop.","evidence":"RNAi, dominant-negative overexpression, TCF/LEF reporters in HEK293 and SW480 cells","pmids":["18627596"],"confidence":"Medium","gaps":["Identity of the C-terminal ligand left unknown","Single lab; limited cell-line contexts"]},{"year":2008,"claim":"Located a C-terminal transcriptional activation domain in BCL9 that synergizes with β-catenin's transactivation domain and partly bypasses Pygo, linking BCL9 to histone-acetyltransferase coactivators.","evidence":"Luciferase reporters, deletion/mutation analysis, Co-IP in lymphoid and non-lymphoid lines","pmids":["18347063"],"confidence":"Medium","gaps":["Direct BCL9–CBP/p300 binding inferred via β-catenin, not demonstrated independently","Pygo-independent activity not fully mapped to a domain"]},{"year":2009,"claim":"Connected BCL9 to oncogenic phenotypes in vivo, showing it drives proliferation, invasion, metastasis and angiogenesis through canonical Wnt target genes.","evidence":"RNAi/overexpression, migration/invasion assays, xenograft mouse models","pmids":["19738061"],"confidence":"Medium","gaps":["Causality between specific targets and phenotype correlative","Single lab"]},{"year":2009,"claim":"Demonstrated a physiological requirement for BCL9/BCL9-2 in Wnt activation during muscle regeneration, linking the adaptor to nuclear β-catenin localization and differentiation.","evidence":"Cre-lox conditional knockout, RNAi, β-catenin immunofluorescence, reporter assays","pmids":["19699733"],"confidence":"High","gaps":["Target genes governing myogenic differentiation not defined","Tissue specificity of requirement unexplained"]},{"year":2010,"claim":"Defined BCL9/BCL9l as selectively required for a Wnt-dependent stem-cell and EMT transcriptional program in intestine and adenocarcinoma, distinguishing it from global Wnt signaling.","evidence":"Intestine-specific conditional knockout, transcriptional profiling, histology","pmids":["20682801"],"confidence":"High","gaps":["Molecular basis of program selectivity unresolved","Distinction from generic Wnt targets at the chromatin level not mapped"]},{"year":2012,"claim":"Provided pharmacological proof that the BCL9 HD2–β-catenin interface is essential and druggable, by using a stabilized α-helix to dissociate the complex and suppress tumor growth.","evidence":"Stabilized α-helix peptide, Co-IP disruption, reporter and xenograft models","pmids":["22914623"],"confidence":"High","gaps":["Specificity for BCL9 over other armadillo ligands in vivo not exhaustively shown","Resistance mechanisms not explored"]},{"year":2013,"claim":"Identified an endogenous brake on BCL9 recruitment: LATS2 binds β-catenin and disrupts the β-catenin/BCL9 interaction independently of its kinase activity.","evidence":"Reciprocal Co-IP, ChIP on Wnt promoters, kinase-dead mutant analysis","pmids":["24360964"],"confidence":"Medium","gaps":["Structural basis of LATS2 competition unknown","Single lab"]},{"year":2017,"claim":"Reframed BCL9/B9L as constitutive enhanceosome components, showing the C-terminus binds Groucho/TLE and the LDB1-SSDP core, with a Wnt-triggered rearrangement apposing it to TCF.","evidence":"CRISPR/Cas9 engineering, BioID proximity labeling, Co-IP across Drosophila and human cells","pmids":["28296634"],"confidence":"High","gaps":["Structural detail of the C-terminus–TLE/core contacts not resolved here","How the activation switch is triggered mechanistically unclear"]},{"year":2017,"claim":"Linked hypoxia to Wnt coactivator dosage, showing HIF-1α (but not HIF-2α) directly induces BCL9 via promoter HREs in colorectal cancer.","evidence":"BCL9 promoter luciferase reporters with HRE mutation, HIF overexpression/siRNA, ChIP","pmids":["27121066"],"confidence":"Medium","gaps":["Physiological contribution of hypoxic induction to tumor Wnt activity not quantified","Single lab"]},{"year":2017,"claim":"Reported SOX7 as a competitive antagonist that displaces BCL9 from β-catenin to suppress oncogenic transcription.","evidence":"Co-IP, TCF/LEF reporters, competitive binding analysis","pmids":["29271667"],"confidence":"Low","gaps":["Single Co-IP and reporter assay without reciprocal/structural validation","Limited mechanistic follow-up; single lab"]},{"year":2018,"claim":"Uncovered a mitotic, cell-cycle-coupled regulation of BCL9 in which CDK1 phosphorylation at Thr172 limits clathrin-mediated LRP6 degradation to sustain mitotic Wnt signaling.","evidence":"Mitotic interactome MS, Co-IP, T172A phospho-mutant, cell division assays","pmids":["30217955"],"confidence":"Medium","gaps":["Direct BCL9–clathrin contact and stoichiometry not fully defined","Single lab"]},{"year":2018,"claim":"Demonstrated tissue-selective β-catenin cofactor function by showing the β-catenin–BCL9–Pygo complex is specifically required for cardiac developmental Wnt programs while other Wnt responses persist.","evidence":"Combined Bcl9/Pygo mutants in zebrafish and mouse, cardiac gene expression analysis","pmids":["30366904"],"confidence":"High","gaps":["Why cardiac targets depend selectively on BCL9/Pygo unresolved","Direct chromatin targets not enumerated"]},{"year":2019,"claim":"Showed genetically that BCL9/Bcl9l are required for β-catenin-driven intestinal and hepatic transformation and cooperate with Pygo to shift gene expression from stem-cell-like to secretory differentiation.","evidence":"ApcMin/Apc1322T conditional knockouts, genetic synergy with Pygo deletion, expression profiling","pmids":["30760720","30760710"],"confidence":"High","gaps":["Mechanism linking BCL9/Pygo loss to Notch-driven differentiation not detailed","Selectivity over normal homeostatic Wnt incompletely explained"]},{"year":2020,"claim":"Identified a β-catenin-independent function for BCL9 in stabilizing calcium-signaling and neural mRNAs via paraspeckle proteins under calcium/stress signaling.","evidence":"Co-IP with paraspeckle proteins, RNA-IP, live-cell calcium imaging, siRNA in colorectal cancer cells","pmids":["31911584"],"confidence":"Medium","gaps":["Direct RNA-binding versus indirect recruitment not distinguished","Single lab; novel mechanism not independently replicated"]},{"year":2020,"claim":"Extended BCL9's transcriptional partnerships beyond β-catenin by showing it co-occupies enhancers with phospho-S727 STAT3 to drive invasive DCIS target genes.","evidence":"ChIP-exo, RNA-seq, BCL9 siRNA in a PDX DCIS MIND model","pmids":["32352029"],"confidence":"Medium","gaps":["Direct BCL9–STAT3 binding versus co-recruitment unresolved","Single lab"]},{"year":2023,"claim":"Resolved how BCL9-Pygo integrates into the enhanceosome core, showing a single LDB1-SSBP2 complex binds two Pygo NPF motifs in a deep groove and that LDB/Pygo loss impairs Wnt transcription.","evidence":"X-ray crystallography of Pygo2/LDB1/SSBP2, Co-IP, CRISPR knockouts with reporter assays","pmids":["37349336"],"confidence":"High","gaps":["Stoichiometry and architecture of the full BCL9-containing enhanceosome not resolved","Dynamics of the Wnt-triggered rearrangement not captured structurally"]},{"year":2024,"claim":"Reported a BCL9–Nrf2 interaction that modulates ferroptosis susceptibility in thyroid carcinoma, extending BCL9 into redox/cell-death control.","evidence":"Co-IP, siRNA knockdown, ferroptosis assays, xenograft model","pmids":["39291848"],"confidence":"Low","gaps":["Single Co-IP from one lab; interaction not independently replicated","Direct versus indirect effect on Nrf2 stability not established"]},{"year":null,"claim":"How BCL9 achieves context- and tissue-selective Wnt target gene activation—and how its β-catenin-independent RNA-stabilizing, mitotic, and redox functions are integrated—remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of the complete BCL9-containing enhanceosome on chromatin","Molecular determinant of program selectivity unknown","Relationship among the distinct β-catenin-independent activities uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,12]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[6,12,21]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[2]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[17]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,8,12]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[2,21]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,5,12]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[6,12,18]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[8,9,15]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,16]}],"complexes":["Wnt enhanceosome","β-catenin/BCL9/TCF complex","Pygo-BCL9-LDB1-SSBP core complex"],"partners":["CTNNB1","PYGO2","TCF7L2","LDB1","SSBP2","TLE","STAT3","NFE2L2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O00512","full_name":"B-cell CLL/lymphoma 9 protein","aliases":["Protein legless homolog"],"length_aa":1426,"mass_kda":149.3,"function":"Involved in signal transduction through the Wnt pathway. Promotes beta-catenin's transcriptional activity (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/O00512/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BCL9","classification":"Not Classified","n_dependent_lines":170,"n_total_lines":1208,"dependency_fraction":0.14072847682119205},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BCL9","total_profiled":1310},"omim":[{"mim_id":"609004","title":"B-CELL CLL/LYMPHOMA 9-LIKE; BCL9L","url":"https://www.omim.org/entry/609004"},{"mim_id":"607393","title":"CELL DIVISION CYCLE 73; CDC73","url":"https://www.omim.org/entry/607393"},{"mim_id":"606903","title":"PYGOPUS FAMILY PHD FINGER 2; PYGO2","url":"https://www.omim.org/entry/606903"},{"mim_id":"606902","title":"PYGOPUS FAMILY PHD FINGER 1; PYGO1","url":"https://www.omim.org/entry/606902"},{"mim_id":"605877","title":"Fc RECEPTOR-LIKE PROTEIN 5; FCRL5","url":"https://www.omim.org/entry/605877"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Nuclear bodies","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BCL9"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O00512","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O00512","model_url":"https://alphafold.ebi.ac.uk/files/AF-O00512-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O00512-F1-predicted_aligned_error_v6.png","plddt_mean":42.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCL9","jax_strain_url":"https://www.jax.org/strain/search?query=BCL9"},"sequence":{"accession":"O00512","fasta_url":"https://rest.uniprot.org/uniprotkb/O00512.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O00512/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O00512"}},"corpus_meta":[{"pmid":"11955446","id":"PMC_11955446","title":"Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/11955446","citation_count":490,"is_preprint":false},{"pmid":"15371335","id":"PMC_15371335","title":"Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions.","date":"2004","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/15371335","citation_count":273,"is_preprint":false},{"pmid":"22914623","id":"PMC_22914623","title":"Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.","date":"2012","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22914623","citation_count":221,"is_preprint":false},{"pmid":"22196480","id":"PMC_22196480","title":"Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction.","date":"2012","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22196480","citation_count":186,"is_preprint":false},{"pmid":"17052462","id":"PMC_17052462","title":"Crystal structure of a beta-catenin/BCL9/Tcf4 complex.","date":"2006","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/17052462","citation_count":171,"is_preprint":false},{"pmid":"19738061","id":"PMC_19738061","title":"BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19738061","citation_count":164,"is_preprint":false},{"pmid":"24599134","id":"PMC_24599134","title":"miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24599134","citation_count":162,"is_preprint":false},{"pmid":"18498752","id":"PMC_18498752","title":"Decoding of methylated histone H3 tail by the Pygo-BCL9 Wnt signaling complex.","date":"2008","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/18498752","citation_count":145,"is_preprint":false},{"pmid":"9490669","id":"PMC_9490669","title":"Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9490669","citation_count":138,"is_preprint":false},{"pmid":"20682801","id":"PMC_20682801","title":"Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20682801","citation_count":109,"is_preprint":false},{"pmid":"27507882","id":"PMC_27507882","title":"MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents.","date":"2016","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27507882","citation_count":97,"is_preprint":false},{"pmid":"18627596","id":"PMC_18627596","title":"The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells.","date":"2008","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18627596","citation_count":97,"is_preprint":false},{"pmid":"31086813","id":"PMC_31086813","title":"Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells.","date":"2019","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/31086813","citation_count":95,"is_preprint":false},{"pmid":"19699733","id":"PMC_19699733","title":"BCL9 is an essential component of canonical Wnt signaling that mediates the differentiation of myogenic progenitors during muscle regeneration.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19699733","citation_count":79,"is_preprint":false},{"pmid":"15574752","id":"PMC_15574752","title":"Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15574752","citation_count":79,"is_preprint":false},{"pmid":"28074862","id":"PMC_28074862","title":"Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28074862","citation_count":77,"is_preprint":false},{"pmid":"28296634","id":"PMC_28296634","title":"Constitutive scaffolding of multiple Wnt enhanceosome components by Legless/BCL9.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/28296634","citation_count":74,"is_preprint":false},{"pmid":"30760720","id":"PMC_30760720","title":"Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30760720","citation_count":71,"is_preprint":false},{"pmid":"28817119","id":"PMC_28817119","title":"miR-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt/β-catenin signaling through targeting BCL9.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28817119","citation_count":65,"is_preprint":false},{"pmid":"24360964","id":"PMC_24360964","title":"LATS2 suppresses oncogenic Wnt signaling by disrupting β-catenin/BCL9 interaction.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/24360964","citation_count":59,"is_preprint":false},{"pmid":"28769030","id":"PMC_28769030","title":"miR-30a acts as a tumor suppressor by double-targeting COX-2 and BCL9 in H. pylori gastric cancer models.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28769030","citation_count":55,"is_preprint":false},{"pmid":"22024689","id":"PMC_22024689","title":"MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor-induced cellular proliferation and downregulates the oncogene BCL9.","date":"2011","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/22024689","citation_count":54,"is_preprint":false},{"pmid":"18347063","id":"PMC_18347063","title":"Cell-type-specific function of BCL9 involves a transcriptional activation domain that synergizes with beta-catenin.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18347063","citation_count":49,"is_preprint":false},{"pmid":"26844272","id":"PMC_26844272","title":"BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer.","date":"2015","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/26844272","citation_count":48,"is_preprint":false},{"pmid":"21703997","id":"PMC_21703997","title":"BCL9-2 promotes early stages of intestinal tumor progression.","date":"2011","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/21703997","citation_count":47,"is_preprint":false},{"pmid":"33838016","id":"PMC_33838016","title":"miR-140-3p inhibits colorectal cancer progression and its liver metastasis by targeting BCL9 and BCL2.","date":"2021","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33838016","citation_count":41,"is_preprint":false},{"pmid":"35368023","id":"PMC_35368023","title":"Endometrial epithelial cells-derived exosomes deliver microRNA-30c to block the BCL9/Wnt/CD44 signaling and inhibit cell invasion and migration in ovarian endometriosis.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35368023","citation_count":41,"is_preprint":false},{"pmid":"23382809","id":"PMC_23382809","title":"BCL9 and C9orf5 are associated with negative symptoms in schizophrenia: meta-analysis of two genome-wide association studies.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23382809","citation_count":41,"is_preprint":false},{"pmid":"30366904","id":"PMC_30366904","title":"Mutations in Bcl9 and Pygo genes cause congenital heart defects by tissue-specific perturbation of Wnt/β-catenin signaling.","date":"2018","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/30366904","citation_count":37,"is_preprint":false},{"pmid":"35229987","id":"PMC_35229987","title":"miRNA-122-5p in POI ovarian-derived exosomes promotes granulosa cell apoptosis by regulating BCL9.","date":"2022","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35229987","citation_count":36,"is_preprint":false},{"pmid":"33767438","id":"PMC_33767438","title":"BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33767438","citation_count":35,"is_preprint":false},{"pmid":"21383261","id":"PMC_21383261","title":"Common variants in the BCL9 gene conferring risk of schizophrenia.","date":"2011","source":"Archives of general psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/21383261","citation_count":34,"is_preprint":false},{"pmid":"34417435","id":"PMC_34417435","title":"BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer.","date":"2021","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34417435","citation_count":33,"is_preprint":false},{"pmid":"31911584","id":"PMC_31911584","title":"BCL9 provides multi-cellular communication properties in colorectal cancer by interacting with paraspeckle proteins.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31911584","citation_count":33,"is_preprint":false},{"pmid":"17113272","id":"PMC_17113272","title":"BCL9-2 binds Arm/beta-catenin in a Tyr142-independent manner and requires Pygopus for its function in Wg/Wnt signaling.","date":"2006","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/17113272","citation_count":32,"is_preprint":false},{"pmid":"19715304","id":"PMC_19715304","title":"Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction.","date":"2009","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19715304","citation_count":32,"is_preprint":false},{"pmid":"30909141","id":"PMC_30909141","title":"LncRNA SNHG16 promotes proliferation, migration and invasion of osteosarcoma cells by targeting miR-1301/BCL9 axis.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30909141","citation_count":31,"is_preprint":false},{"pmid":"35486727","id":"PMC_35486727","title":"A novel β-catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35486727","citation_count":31,"is_preprint":false},{"pmid":"31440992","id":"PMC_31440992","title":"Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma.","date":"2019","source":"Hepatology international","url":"https://pubmed.ncbi.nlm.nih.gov/31440992","citation_count":30,"is_preprint":false},{"pmid":"26998113","id":"PMC_26998113","title":"BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression.","date":"2016","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26998113","citation_count":30,"is_preprint":false},{"pmid":"30760710","id":"PMC_30760710","title":"Bcl9 and Pygo synergise downstream of Apc to effect intestinal neoplasia in FAP mouse models.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30760710","citation_count":28,"is_preprint":false},{"pmid":"34545187","id":"PMC_34545187","title":"The interactions of Bcl9/Bcl9L with β-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34545187","citation_count":24,"is_preprint":false},{"pmid":"30009824","id":"PMC_30009824","title":"BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.","date":"2018","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30009824","citation_count":24,"is_preprint":false},{"pmid":"31561723","id":"PMC_31561723","title":"MicroRNA-3194-3p inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by decreasing Wnt/β-catenin signaling through targeting BCL9.","date":"2019","source":"Artificial cells, nanomedicine, and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/31561723","citation_count":24,"is_preprint":false},{"pmid":"30472057","id":"PMC_30472057","title":"MiR-532 downregulation of the Wnt/β-catenin signaling via targeting Bcl-9 and induced human intervertebral disc nucleus pulposus cells apoptosis.","date":"2018","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30472057","citation_count":24,"is_preprint":false},{"pmid":"30217955","id":"PMC_30217955","title":"CDK1-mediated BCL9 phosphorylation inhibits clathrin to promote mitotic Wnt signalling.","date":"2018","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/30217955","citation_count":23,"is_preprint":false},{"pmid":"35027586","id":"PMC_35027586","title":"Hypoxia-inducible factor 1α induces osteo/odontoblast differentiation of human dental pulp stem cells via Wnt/β-catenin transcriptional cofactor BCL9.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35027586","citation_count":21,"is_preprint":false},{"pmid":"38811552","id":"PMC_38811552","title":"Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration.","date":"2024","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38811552","citation_count":20,"is_preprint":false},{"pmid":"30172867","id":"PMC_30172867","title":"MicroRNA-1301 inhibits migration and invasion of osteosarcoma cells by targeting BCL9.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30172867","citation_count":20,"is_preprint":false},{"pmid":"29271667","id":"PMC_29271667","title":"SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction.","date":"2017","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29271667","citation_count":20,"is_preprint":false},{"pmid":"25149534","id":"PMC_25149534","title":"The BCL9-2 proto-oncogene governs estrogen receptor alpha expression in breast tumorigenesis.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25149534","citation_count":19,"is_preprint":false},{"pmid":"31616187","id":"PMC_31616187","title":"Long non-coding RNA NNT-AS1 functions as an oncogenic gene through modulating miR-485/BCL9 in cholangiocarcinoma.","date":"2019","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/31616187","citation_count":19,"is_preprint":false},{"pmid":"33974352","id":"PMC_33974352","title":"LncRNA NCK1-AS1 exerts oncogenic property in gastric cancer by targeting the miR-22-3p/BCL9 axis to activate the Wnt/β-catenin signaling.","date":"2021","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/33974352","citation_count":19,"is_preprint":false},{"pmid":"31751960","id":"PMC_31751960","title":"Targeted disruption of the BCL9/β-catenin interaction by endosomal-escapable nanoparticles functionalized with an E-cadherin-derived peptide.","date":"2019","source":"Nanotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/31751960","citation_count":18,"is_preprint":false},{"pmid":"34396632","id":"PMC_34396632","title":"Long noncoding RNA NEAT1 promotes tumorigenesis in H. pylori gastric cancer by sponging miR-30a to regulate COX-2/BCL9 pathway.","date":"2021","source":"Helicobacter","url":"https://pubmed.ncbi.nlm.nih.gov/34396632","citation_count":17,"is_preprint":false},{"pmid":"34660593","id":"PMC_34660593","title":"Circular RNA circFNDC3AL Upregulates BCL9 Expression to Promote Chicken Skeletal Muscle Satellite Cells Proliferation and Differentiation by Binding to miR-204.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34660593","citation_count":17,"is_preprint":false},{"pmid":"32352029","id":"PMC_32352029","title":"BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression.","date":"2020","source":"NPJ breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32352029","citation_count":17,"is_preprint":false},{"pmid":"17129358","id":"PMC_17129358","title":"Up-regulation of a BCL9-related beta-catenin-binding protein, B9L, in different stages of sporadic colorectal adenoma.","date":"2007","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/17129358","citation_count":15,"is_preprint":false},{"pmid":"29428231","id":"PMC_29428231","title":"BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.","date":"2018","source":"Journal of the American College of Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/29428231","citation_count":14,"is_preprint":false},{"pmid":"28103279","id":"PMC_28103279","title":"Aristaless Related Homeobox (ARX) Interacts with β-Catenin, BCL9, and P300 to Regulate Canonical Wnt Signaling.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28103279","citation_count":14,"is_preprint":false},{"pmid":"34566638","id":"PMC_34566638","title":"Inhibition of BCL9 Modulates the Cellular Landscape of Tumor-Associated Macrophages in the Tumor Immune Microenvironment of Colorectal Cancer.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34566638","citation_count":14,"is_preprint":false},{"pmid":"27121066","id":"PMC_27121066","title":"HIF-1α activates hypoxia-induced BCL-9 expression in human colorectal cancer cells.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27121066","citation_count":14,"is_preprint":false},{"pmid":"25678599","id":"PMC_25678599","title":"The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells.","date":"2015","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/25678599","citation_count":13,"is_preprint":false},{"pmid":"27314976","id":"PMC_27314976","title":"Differentially expressed microRNA-218 modulates the viability of renal cell carcinoma by regulating BCL9.","date":"2016","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/27314976","citation_count":12,"is_preprint":false},{"pmid":"33821684","id":"PMC_33821684","title":"LncRNA MNX1-AS1 Contributes to Laryngeal Squamous Cell Carcinoma Growth and Migration by Regulating mir-744-5p/bcl9/β-Catenin Axis.","date":"2021","source":"Cell transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/33821684","citation_count":11,"is_preprint":false},{"pmid":"37349336","id":"PMC_37349336","title":"Structural basis of the interaction between BCL9-Pygo and LDB-SSBP complexes in assembling the Wnt enhanceosome.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37349336","citation_count":10,"is_preprint":false},{"pmid":"31827404","id":"PMC_31827404","title":"Low BCL9 expression inhibited ovarian epithelial malignant tumor progression by decreasing proliferation, migration, and increasing apoptosis to cancer cells.","date":"2019","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/31827404","citation_count":10,"is_preprint":false},{"pmid":"34026600","id":"PMC_34026600","title":"Pharmacological Inhibition and Genetic Knockdown of BCL9 Modulate the Cellular Landscape of Cancer-Associated Fibroblasts in the Tumor-Immune Microenvironment of Colorectal Cancer.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34026600","citation_count":10,"is_preprint":false},{"pmid":"31081087","id":"PMC_31081087","title":"MiR-30c exerts tumor suppressive functions in colorectal carcinoma by directly targeting BCL9.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31081087","citation_count":10,"is_preprint":false},{"pmid":"38335808","id":"PMC_38335808","title":"Decoding the dynamics of BCL9 triazole stapled peptide.","date":"2024","source":"Biophysical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38335808","citation_count":8,"is_preprint":false},{"pmid":"37692512","id":"PMC_37692512","title":"The Wnt-dependent and Wnt-independent functions of BCL9 in development, tumorigenesis, and immunity: Implications in therapeutic opportunities.","date":"2023","source":"Genes & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/37692512","citation_count":8,"is_preprint":false},{"pmid":"35586435","id":"PMC_35586435","title":"New ZW4864 Derivatives as Small-Molecule Inhibitors for the β-Catenin/BCL9 Protein-Protein Interaction.","date":"2022","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/35586435","citation_count":8,"is_preprint":false},{"pmid":"33552975","id":"PMC_33552975","title":"Bcl9 Depletion Modulates Endothelial Cell in Tumor Immune Microenvironment in Colorectal Cancer Tumor.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33552975","citation_count":8,"is_preprint":false},{"pmid":"33862557","id":"PMC_33862557","title":"Evidence for frequent concurrent DCUN1D1, FGFR1, BCL9 gene copy number amplification in squamous cell lung cancer.","date":"2021","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/33862557","citation_count":7,"is_preprint":false},{"pmid":"26494551","id":"PMC_26494551","title":"Association study of BCL9 gene polymorphism rs583583 with schizophrenia and negative symptoms in Japanese population.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26494551","citation_count":7,"is_preprint":false},{"pmid":"35745877","id":"PMC_35745877","title":"Turning a Targeting β-Catenin/Bcl9 Peptide Inhibitor into a GdOF@Au Core/Shell Nanoflower for Enhancing Immune Response to Cancer Therapy in Combination with Immune Checkpoint Inhibitors.","date":"2022","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/35745877","citation_count":7,"is_preprint":false},{"pmid":"17020613","id":"PMC_17020613","title":"Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.","date":"2006","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17020613","citation_count":7,"is_preprint":false},{"pmid":"33849283","id":"PMC_33849283","title":"Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors.","date":"2021","source":"Future medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33849283","citation_count":5,"is_preprint":false},{"pmid":"41249197","id":"PMC_41249197","title":"Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41249197","citation_count":4,"is_preprint":false},{"pmid":"37881428","id":"PMC_37881428","title":"Modulating β-catenin/BCL9 interaction with cell-membrane-camouflaged carnosic acid to inhibit Wnt pathway and enhance tumor immune response.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37881428","citation_count":4,"is_preprint":false},{"pmid":"35023882","id":"PMC_35023882","title":"Nuclear Expression of Pygo2 Correlates with Poorly Differentiated State Involving c-Myc, PCNA and Bcl9 in Myanmar Hepatocellular Carcinoma.","date":"2021","source":"Acta histochemica et cytochemica","url":"https://pubmed.ncbi.nlm.nih.gov/35023882","citation_count":4,"is_preprint":false},{"pmid":"30013632","id":"PMC_30013632","title":"Expression of miR-30c and BCL-9 in gastric carcinoma tissues and their function in the development of gastric cancer.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30013632","citation_count":4,"is_preprint":false},{"pmid":"38645401","id":"PMC_38645401","title":"BCL9 is a Risk Factor of Neck Lymph Nodes Metastasis and Correlated with Immune Cell Infiltration in Papillary Thyroid Carcinoma.","date":"2024","source":"International journal of general medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38645401","citation_count":2,"is_preprint":false},{"pmid":"34978646","id":"PMC_34978646","title":"The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients.","date":"2022","source":"Journal, genetic engineering & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/34978646","citation_count":2,"is_preprint":false},{"pmid":"26711608","id":"PMC_26711608","title":"[Association of BCL9 expression with prostate cancer clinicopathological features and survival].","date":"2015","source":"Zhonghua yi xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/26711608","citation_count":2,"is_preprint":false},{"pmid":"41222773","id":"PMC_41222773","title":"BCL9 as a Key Player in Wnt/β-catenin Signaling: Implications for Osteogenesis, Tissue Repair, and Oncology.","date":"2025","source":"Applied biochemistry and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/41222773","citation_count":2,"is_preprint":false},{"pmid":"39291848","id":"PMC_39291848","title":"Dysregulated BCL9 Controls Tumorigenicity and Ferroptosis Susceptibility by Binding With Nrf2 in Thyroid Carcinoma.","date":"2024","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/39291848","citation_count":1,"is_preprint":false},{"pmid":"40366806","id":"PMC_40366806","title":"GATA1-mediated Notch signaling augment antitumor immunity of CD11b+CD27- natural killer cells maturation via BCL9/β-catenin signal.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/40366806","citation_count":1,"is_preprint":false},{"pmid":"30923411","id":"PMC_30923411","title":"Immunohistochemical Mapping of Bcl9 Using Two Antibodies that Recognize Different Epitopes Is Useful to Characterize Juvenile Development of Hepatocellular Carcinoma in Myanmar.","date":"2019","source":"Acta histochemica et cytochemica","url":"https://pubmed.ncbi.nlm.nih.gov/30923411","citation_count":1,"is_preprint":false},{"pmid":"33235148","id":"PMC_33235148","title":"MEF2D-BCL9 B-Lymphoblastic Leukemia Blast Morphology Does Not Always Mimic Mature B-Cell Leukemia.","date":"2021","source":"Journal of pediatric hematology/oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33235148","citation_count":1,"is_preprint":false},{"pmid":"40948801","id":"PMC_40948801","title":"Disrupting β-Catenin/BCL9 interaction with a peptide prodrug boosts immunotherapy in colorectal cancer.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40948801","citation_count":0,"is_preprint":false},{"pmid":"40358810","id":"PMC_40358810","title":"CD5-positive B-cell acute lymphoblastic leukemia/lymphoma with MEF2D::BCL9 mimicking aggressive mature B-cell lymphoma: a case report of a newly described entity and potential diagnostic pitfall.","date":"2025","source":"Journal of hematopathology","url":"https://pubmed.ncbi.nlm.nih.gov/40358810","citation_count":0,"is_preprint":false},{"pmid":"40736291","id":"PMC_40736291","title":"LINC01232 regulates miR-516a-5p/BCL9 axis to promote triple-negative breast cancer progression.","date":"2025","source":"Cellular and molecular biology (Noisy-le-Grand, France)","url":"https://pubmed.ncbi.nlm.nih.gov/40736291","citation_count":0,"is_preprint":false},{"pmid":"41563498","id":"PMC_41563498","title":"The GC-derived exosomal LncRNA DARS-AS1 activates Wnt/β-catenin pathway to drive angiogenesis by regulating miR-605-5p/BCL9.","date":"2026","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41563498","citation_count":0,"is_preprint":false},{"pmid":"42190771","id":"PMC_42190771","title":"Disruption of BCL9-β-catenin interaction by de novo designed miniproteins inhibits oncogenic signaling.","date":"2026","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/42190771","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.28.672450","title":"Determination of Copy Number Variations and Affected Gene Networks in Breast Cancer from Mexican Patients","date":"2025-08-31","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.28.672450","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48856,"output_tokens":5481,"usd":0.114391,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14134,"output_tokens":6536,"usd":0.117035,"stage2_stop_reason":"end_turn"},"total_usd":0.231426,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"BCL9 (Drosophila ortholog Legless/Lgs) physically links Pygopus (Pygo) to nuclear β-catenin, thereby recruiting Pygo to the β-catenin–TCF complex and enabling Wnt transcriptional activation. Genetic and molecular (co-IP, epistasis) evidence established this adaptor function.\",\n      \"method\": \"Genetic epistasis in Drosophila, co-immunoprecipitation, domain mapping\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic epistasis combined with molecular co-IP in founding paper; independently replicated across multiple subsequent labs\",\n      \"pmids\": [\"11955446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Crystal structure of a β-catenin/BCL9/Tcf-4 triple complex at 2.6 Å resolution revealed that BCL9's β-catenin-binding domain (CBD) forms an α-helix that contacts the first armadillo repeat of β-catenin — a site distinct from cadherin/α-catenin binding. Mutation of this armadillo repeat abolished BCL9 binding without disrupting cadherin interactions.\",\n      \"method\": \"X-ray crystallography (2.6 Å), structure-guided mutagenesis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution structure with functional mutagenesis validating the binding interface\",\n      \"pmids\": [\"17052462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The BCL9/Legless HD1 domain forms a ternary complex with the Pygo PHD finger to bind specifically to histone H3 methylated at lysine 4 (H3K4me2). HD1 association is required for efficient H3K4me binding, and this histone-decoding function is necessary for Wnt signaling outputs in Drosophila rescue experiments.\",\n      \"method\": \"Crystal structures of PHD–HD1–H3K4me peptide ternary complexes; ITC binding assays; Drosophila rescue genetics\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple crystal structures plus functional rescue in vivo; single lab but orthogonal methods\",\n      \"pmids\": [\"18498752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"BCL9-2 (B9L) binding to β-catenin modulates the switch between β-catenin's adhesive and transcriptional functions. Phosphorylation of Tyr142 of β-catenin favors BCL9-2 binding and precludes α-catenin interaction, thereby promoting nuclear (transcriptional) over membrane (adhesive) β-catenin function. RNAi of BCL9-2 in carcinoma cells induces epithelial phenotype and relocates β-catenin from nucleus to membrane.\",\n      \"method\": \"RNAi knockdown, co-immunoprecipitation, phosphorylation site mutagenesis, zebrafish epistasis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (RNAi, Co-IP, mutagenesis, in vivo zebrafish); single lab; Tyr142 mechanism later questioned by Hoffmans 2006\",\n      \"pmids\": [\"15371335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BCL9-2 can functionally replace Drosophila Legless (BCL9) in vivo and in cultured cells, and this rescue requires the ability of BCL9-2 to bind Pygo; the Tyr142 phosphorylation of β-catenin was found not to be important for BCL9-2 recruitment or transcriptional activity in multiple assays.\",\n      \"method\": \"Drosophila in vivo rescue assays, mammalian cell transcriptional reporter assays, co-immunoprecipitation\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro assays across two systems; single lab; directly contradicts Brembeck 2004 on Tyr142\",\n      \"pmids\": [\"17113272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BCL9 is required for efficient β-catenin-mediated transcription in Wnt-stimulated HEK293 cells and SW480 colorectal cancer cells (APC-mutant). BCL9 function depends on both its β-catenin-binding domain and an unknown C-terminal ligand. BCL9 and B9L/BCL9-2 are Wnt-inducible genes, indicating a positive feedback loop.\",\n      \"method\": \"RNAi knockdown, dominant-negative overexpression, TCF/LEF reporter assays in human cell lines\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — RNAi plus dominant-negative approach; single lab; two cell-line contexts\",\n      \"pmids\": [\"18627596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BCL9 contains a C-terminal transcriptional activation domain that functionally synergizes with β-catenin's C-terminal transactivation domain in lymphoid cells, and this activity is partially Pygopus-independent. The β-catenin transactivation domain associates with histone acetyltransferases CBP/p300 and TRRAP/GCN5.\",\n      \"method\": \"Luciferase reporter assays, deletion/mutation analysis, co-immunoprecipitation in lymphoid and non-lymphoid cell lines\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — domain deletion analysis plus Co-IP in multiple cell types; single lab\",\n      \"pmids\": [\"18347063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BCL9 enhances β-catenin-mediated transcriptional activity and promotes proliferation, migration, invasion, and metastasis of tumor cells. BCL9 knockdown in xenograft models reduced tumor load, metastasis, and angiogenesis, accompanied by downregulation of c-Myc, cyclin D1, CD44, and VEGF.\",\n      \"method\": \"RNAi knockdown, overexpression, in vitro migration/invasion assays, xenograft mouse models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo functional studies with defined molecular readouts; single lab\",\n      \"pmids\": [\"19738061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BCL9 is required for Wnt/β-catenin cascade activation in adult myogenic progenitors; loss of BCL9/BCL9-2 (via Cre-lox deletion or RNAi) abrogates nuclear β-catenin localization and TCF/LEF-mediated transcription normally observed upon Wnt stimulation, and impairs myogenic differentiation and muscle regeneration.\",\n      \"method\": \"Cre-lox conditional knockout in mouse myogenic lineage, RNAi in vitro, β-catenin localization by immunofluorescence, TCF/LEF reporter assays\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo conditional knockout replicated in vitro with RNAi; defined cellular phenotype with molecular readout\",\n      \"pmids\": [\"19699733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Conditional ablation of Bcl9/Bcl9l in mouse intestinal epithelium decreases intestinal stem cell marker expression and impairs colon regeneration. In Wnt-driven adenocarcinomas, loss of Bcl9/Bcl9l abrogates EMT and stem-cell-like transcriptional programs, demonstrating that BCL9/BCL9l are specifically required for a Wnt-dependent stem cell and EMT gene expression program.\",\n      \"method\": \"Conditional knockout mouse genetics (intestine-specific Cre), transcriptional profiling, histology\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO in vivo with defined molecular and phenotypic readouts; replicated in tumor context\",\n      \"pmids\": [\"20682801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A stabilized α-helix of BCL9 (SAH-BCL9) that mimics the BCL9 HD2 domain binds β-catenin, dissociates native β-catenin/BCL9 complexes, and selectively suppresses Wnt transcription. This peptide inhibitor suppresses tumor growth, angiogenesis, invasion, and metastasis in xenograft models, mechanistically validating BCL9 HD2-mediated direct binding to β-catenin as essential for oncogenic Wnt signaling.\",\n      \"method\": \"Stabilized α-helix peptide design, co-immunoprecipitation disruption assays, luciferase reporter, xenograft mouse models\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — peptide reconstitution of binding interface with functional inhibition in vitro and in vivo; mechanistic mutagenesis supported by prior crystal structure\",\n      \"pmids\": [\"22914623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LATS2 inhibits oncogenic Wnt/β-catenin transcription by directly interacting with β-catenin and disrupting the β-catenin/BCL9 interaction, thereby blocking BCL9 recruitment to Wnt target gene promoters. This function is independent of LATS2 kinase activity.\",\n      \"method\": \"Co-immunoprecipitation, ChIP on Wnt target gene promoters, reporter assays, kinase-dead mutant analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and ChIP; kinase-independent mechanism demonstrated; single lab\",\n      \"pmids\": [\"24360964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BCL9 and B9L (BCL9L) are constitutive components of the Wnt enhanceosome. CRISPR/Cas9 engineering and BioID proximity labeling showed that the C-terminus of BCL9/B9L (downstream of the adaptor elements) is required for Wnt responses. The BCL9/B9L C-terminus binds the Groucho/TLE co-repressor and also binds the Chip/LDB1-SSDP enhanceosome core complex via a conserved element. Upon Wnt-dependent β-catenin docking, a rearrangement apposes the BCL9/B9L C-terminus to TCF.\",\n      \"method\": \"CRISPR/Cas9 genome engineering, BioID proximity labeling, co-immunoprecipitation, domain deletion analysis in Drosophila and human cells\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — CRISPR engineering combined with proximity labeling and Co-IP across two organisms; multiple orthogonal methods in one study\",\n      \"pmids\": [\"28296634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HIF-1α transcriptionally induces BCL9 expression in human colorectal cancer cells via two functional hypoxia-responsive elements (HRE-B and HRE-C) in the BCL9 promoter. HIF-2α does not activate BCL9. This establishes a mechanistic link between hypoxia signaling and Wnt/β-catenin coactivator expression.\",\n      \"method\": \"BCL9 promoter luciferase reporter assays with HRE mutations, HIF-1α/2α overexpression and siRNA knockdown, ChIP\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter plus mutagenesis of HREs and siRNA; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"27121066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CDK1 phosphorylates BCL9 at Thr172 (N-terminal) during mitosis. This phosphorylation prevents clathrin-mediated degradation of LRP6 signalosome components by BCL9 interacting with clathrin and Wnt destruction complex components, thereby sustaining mitotic Wnt signaling and promoting precise cell division.\",\n      \"method\": \"Mitotic interactome analysis (MS), co-immunoprecipitation, phospho-site mutagenesis (T172A), cell division assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-defined interactome with Co-IP validation and phospho-mutant functional analysis; single lab\",\n      \"pmids\": [\"30217955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In zebrafish and mouse, disrupting the β-catenin–BCL9–Pygo complex by combined Bcl9/Pygo mutations causes congenital heart defects with broadly maintained canonical Wnt responses in other tissues, identifying BCL9 and Pygo as selective β-catenin cofactors for a subset of Wnt-dependent cardiac developmental programs.\",\n      \"method\": \"Zebrafish and mouse genetics (combined Bcl9/Pygo mutants), gene expression analysis of cardiac regulators\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — dual-organism genetic analysis with defined tissue-specific phenotype; convergent results across zebrafish and mouse\",\n      \"pmids\": [\"30366904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Intestinal deletion of Bcl9/Bcl9l suppresses Wnt pathway deregulation following APC loss, reduces intestinal tumour growth (especially colonic), and completely abrogates β-catenin-driven intestinal and hepatocellular transformation. Loss of BCL9/9l also synergizes with Pygo loss to shift gene expression from stem-cell-like to Notch-regulated secretory differentiation in Apc-mutant adenomas.\",\n      \"method\": \"Conditional knockout mouse genetics (ApcMin and Apc1322T models), genetic rescue/synergy with Pygo deletion, gene expression profiling\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple in vivo genetic models with mechanistic molecular readouts; two independent Nature Communications papers with convergent findings\",\n      \"pmids\": [\"30760720\", \"30760710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BCL9 has a β-catenin-independent function: in response to calcium transients or cellular stress, BCL9 is recruited to interchromosomal regions where it stabilizes mRNAs of calcium signaling and neural-associated genes by interacting with paraspeckle proteins, thereby sustaining neurotransmitter-dependent communication among colorectal cancer cells.\",\n      \"method\": \"Co-immunoprecipitation with paraspeckle proteins, RNA-IP, live-cell imaging of calcium transients, siRNA knockdown\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — novel β-catenin-independent mechanism supported by Co-IP and RNA-IP; single lab\",\n      \"pmids\": [\"31911584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Crystal structure of a ternary complex comprising the N-terminus of human Pygo2, LDB1, and SSBP2 revealed that BCL9-Pygo assembles with the LDB-SSBP core complex via a conserved N-terminal NPF motif of Pygo2. A single LDB1-SSBP2 complex simultaneously binds two Pygo2 molecules through their NPF motifs, which dock into a deep groove between LDB1 and SSBP2. Loss of LDB or Pygo in human cell lines impairs Wnt/β-catenin-dependent transcription.\",\n      \"method\": \"X-ray crystallography, co-immunoprecipitation, CRISPR/Cas9 human cell line knockouts with reporter assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution crystal structure with functional validation by CRISPR KO; multiple orthogonal methods\",\n      \"pmids\": [\"37349336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SOX7 inhibits oncogenic β-catenin-mediated transcription by competing with BCL9 to bind β-catenin, thereby disrupting the β-catenin/BCL9 interaction.\",\n      \"method\": \"Co-immunoprecipitation, TCF/LEF luciferase reporter assays, competitive binding analysis\",\n      \"journal\": \"DNA and cell biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP and reporter assay; single lab; limited mechanistic follow-up\",\n      \"pmids\": [\"29271667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BCL9 interacts with Nrf2; BCL9 knockdown decreases Nrf2 expression and affects Nrf2 downstream target genes, inducing ferroptosis in thyroid carcinoma cells. Co-IP confirmed the BCL9–Nrf2 physical interaction.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, ferroptosis assays, xenograft mouse model\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP from one lab; novel interaction not independently replicated\",\n      \"pmids\": [\"39291848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BCL9 forms a complex with phosphoserine-727 STAT3 and non-STAT3 transcription factors on chromatin enhancers in DCIS cells. ChIP-exo showed BCL9-pS727-STAT3 co-occupancy at enhancers driving transcription of integrin β3 and MMP16, which mediate DCIS invasive progression.\",\n      \"method\": \"ChIP-exo, RNA sequencing, siRNA knockdown of BCL9 in PDX DCIS MIND model\",\n      \"journal\": \"NPJ breast cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-exo provides genome-wide co-occupancy evidence; functional link via target gene knockdown; single lab\",\n      \"pmids\": [\"32352029\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCL9 functions as an obligate adaptor protein within the Wnt enhanceosome: it physically bridges Pygopus (via its HD1 domain binding the Pygo PHD finger to read H3K4me2) to nuclear β-catenin (via its HD2 α-helical domain contacting armadillo repeat 1), assembles constitutively with the LDB1-SSBP core complex through Pygo's NPF motif, and recruits co-repressor Groucho/TLE and co-activators (CBP/p300, TRRAP/GCN5) through its C-terminus, thereby licensing context-specific Wnt transcriptional activation of TCF/LEF target genes; additionally, BCL9 has β-catenin-independent roles including stabilization of calcium-signaling mRNAs via paraspeckle proteins, regulation of mitotic Wnt signaling through CDK1-mediated Thr172 phosphorylation that inhibits clathrin-mediated LRP6 degradation, and interaction with Nrf2 to modulate ferroptosis susceptibility.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BCL9 is an obligate adaptor protein of the nuclear Wnt/\\u03b2-catenin transcriptional machinery, physically linking the chromatin reader Pygopus to nuclear \\u03b2-catenin and thereby licensing activation of TCF/LEF target genes [#0]. Structurally, its HD2 domain forms an \\u03b1-helix that contacts the first armadillo repeat of \\u03b2-catenin\\u2014a site distinct from the cadherin/\\u03b1-catenin interface\\u2014while its HD1 domain assembles with the Pygo PHD finger to decode H3K4-methylated histones, an interaction required for Wnt output [#1, #2]. Within the Wnt enhanceosome, the BCL9/B9L C-terminus binds the Groucho/TLE co-repressor and the LDB1\\u2013SSBP enhanceosome core, with \\u03b2-catenin docking triggering a rearrangement that apposes the C-terminus to TCF; the Pygo NPF motif anchors BCL9-Pygo to a single LDB1-SSBP2 complex that binds two Pygo molecules [#12, #18]. BCL9 promotes \\u03b2-catenin-driven transcription of oncogenic and stem-cell/EMT programs (c-Myc, cyclin D1, CD44, VEGF), and conditional ablation in mouse intestine and liver abrogates \\u03b2-catenin-driven transformation and EMT while sparing broader Wnt responses, defining BCL9 as a context-selective \\u03b2-catenin cofactor [#7, #9, #16]. This selectivity extends to development, where BCL9/Pygo are required for a subset of cardiac and myogenic Wnt programs [#8, #15]. BCL9 expression is induced by HIF-1\\u03b1 through promoter hypoxia-responsive elements, and disrupting the \\u03b2-catenin\\u2013BCL9 interface with a stabilized HD2 \\u03b1-helix peptide suppresses tumor growth, validating the interaction as a therapeutic target [#10, #13]. Beyond canonical Wnt signaling, BCL9 stabilizes calcium-signaling and neural mRNAs via paraspeckle proteins independently of \\u03b2-catenin [#17], and CDK1 phosphorylates BCL9 at Thr172 during mitosis to sustain mitotic Wnt signaling by limiting clathrin-mediated LRP6 degradation [#14].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established the founding role of BCL9 as the molecular adaptor that recruits Pygopus to the \\u03b2-catenin\\u2013TCF complex, answering how Pygo is brought into Wnt transcriptional control.\",\n      \"evidence\": \"Genetic epistasis in Drosophila (Legless), co-immunoprecipitation and domain mapping\",\n      \"pmids\": [\"11955446\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic basis of the \\u03b2-catenin and Pygo contacts not yet resolved\", \"Identity of additional C-terminal effectors unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined the atomic interface by which BCL9 binds \\u03b2-catenin, showing the HD2 \\u03b1-helix engages armadillo repeat 1 at a site distinct from cadherin/\\u03b1-catenin, explaining how transcriptional and adhesive \\u03b2-catenin pools are separated.\",\n      \"evidence\": \"X-ray crystallography (2.6 \\u00c5) of \\u03b2-catenin/BCL9/Tcf-4 with structure-guided mutagenesis\",\n      \"pmids\": [\"17052462\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address how the interaction is regulated in vivo\", \"Affinity/competition with other armadillo-repeat ligands not quantified\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed that the BCL9 HD1 domain enables Pygo to read H3K4me2, converting the adaptor into part of a histone-decoding module required for Wnt output.\",\n      \"evidence\": \"PHD\\u2013HD1\\u2013H3K4me peptide crystal structures, ITC, Drosophila rescue genetics\",\n      \"pmids\": [\"18498752\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genomic targets of the histone-reading function not mapped\", \"Mechanistic coupling between H3K4me reading and transcriptional activation unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Tested how \\u03b2-catenin's adhesive-versus-transcriptional switch is controlled, proposing that Tyr142 phosphorylation favors BCL9-2 over \\u03b1-catenin binding to drive nuclear function.\",\n      \"evidence\": \"RNAi, Co-IP, phospho-site mutagenesis, zebrafish epistasis in carcinoma cells\",\n      \"pmids\": [\"15371335\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The Tyr142 mechanism was contradicted by subsequent work (idx 4)\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated functional interchangeability of BCL9-2 with Drosophila Legless and showed Pygo binding is essential, while disputing the proposed importance of \\u03b2-catenin Tyr142 phosphorylation.\",\n      \"evidence\": \"Drosophila rescue, mammalian reporter assays, Co-IP\",\n      \"pmids\": [\"17113272\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Conflict with idx 3 on Tyr142 not reconciled within this study\", \"Single lab\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established that BCL9 is required for \\u03b2-catenin-mediated transcription in human Wnt-responsive and APC-mutant colorectal cells and identified an essential but uncharacterized C-terminal ligand, plus a Wnt-inducible feedback loop.\",\n      \"evidence\": \"RNAi, dominant-negative overexpression, TCF/LEF reporters in HEK293 and SW480 cells\",\n      \"pmids\": [\"18627596\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the C-terminal ligand left unknown\", \"Single lab; limited cell-line contexts\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Located a C-terminal transcriptional activation domain in BCL9 that synergizes with \\u03b2-catenin's transactivation domain and partly bypasses Pygo, linking BCL9 to histone-acetyltransferase coactivators.\",\n      \"evidence\": \"Luciferase reporters, deletion/mutation analysis, Co-IP in lymphoid and non-lymphoid lines\",\n      \"pmids\": [\"18347063\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct BCL9\\u2013CBP/p300 binding inferred via \\u03b2-catenin, not demonstrated independently\", \"Pygo-independent activity not fully mapped to a domain\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Connected BCL9 to oncogenic phenotypes in vivo, showing it drives proliferation, invasion, metastasis and angiogenesis through canonical Wnt target genes.\",\n      \"evidence\": \"RNAi/overexpression, migration/invasion assays, xenograft mouse models\",\n      \"pmids\": [\"19738061\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causality between specific targets and phenotype correlative\", \"Single lab\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated a physiological requirement for BCL9/BCL9-2 in Wnt activation during muscle regeneration, linking the adaptor to nuclear \\u03b2-catenin localization and differentiation.\",\n      \"evidence\": \"Cre-lox conditional knockout, RNAi, \\u03b2-catenin immunofluorescence, reporter assays\",\n      \"pmids\": [\"19699733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Target genes governing myogenic differentiation not defined\", \"Tissue specificity of requirement unexplained\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined BCL9/BCL9l as selectively required for a Wnt-dependent stem-cell and EMT transcriptional program in intestine and adenocarcinoma, distinguishing it from global Wnt signaling.\",\n      \"evidence\": \"Intestine-specific conditional knockout, transcriptional profiling, histology\",\n      \"pmids\": [\"20682801\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of program selectivity unresolved\", \"Distinction from generic Wnt targets at the chromatin level not mapped\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Provided pharmacological proof that the BCL9 HD2\\u2013\\u03b2-catenin interface is essential and druggable, by using a stabilized \\u03b1-helix to dissociate the complex and suppress tumor growth.\",\n      \"evidence\": \"Stabilized \\u03b1-helix peptide, Co-IP disruption, reporter and xenograft models\",\n      \"pmids\": [\"22914623\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specificity for BCL9 over other armadillo ligands in vivo not exhaustively shown\", \"Resistance mechanisms not explored\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified an endogenous brake on BCL9 recruitment: LATS2 binds \\u03b2-catenin and disrupts the \\u03b2-catenin/BCL9 interaction independently of its kinase activity.\",\n      \"evidence\": \"Reciprocal Co-IP, ChIP on Wnt promoters, kinase-dead mutant analysis\",\n      \"pmids\": [\"24360964\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of LATS2 competition unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Reframed BCL9/B9L as constitutive enhanceosome components, showing the C-terminus binds Groucho/TLE and the LDB1-SSDP core, with a Wnt-triggered rearrangement apposing it to TCF.\",\n      \"evidence\": \"CRISPR/Cas9 engineering, BioID proximity labeling, Co-IP across Drosophila and human cells\",\n      \"pmids\": [\"28296634\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural detail of the C-terminus\\u2013TLE/core contacts not resolved here\", \"How the activation switch is triggered mechanistically unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked hypoxia to Wnt coactivator dosage, showing HIF-1\\u03b1 (but not HIF-2\\u03b1) directly induces BCL9 via promoter HREs in colorectal cancer.\",\n      \"evidence\": \"BCL9 promoter luciferase reporters with HRE mutation, HIF overexpression/siRNA, ChIP\",\n      \"pmids\": [\"27121066\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological contribution of hypoxic induction to tumor Wnt activity not quantified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Reported SOX7 as a competitive antagonist that displaces BCL9 from \\u03b2-catenin to suppress oncogenic transcription.\",\n      \"evidence\": \"Co-IP, TCF/LEF reporters, competitive binding analysis\",\n      \"pmids\": [\"29271667\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single Co-IP and reporter assay without reciprocal/structural validation\", \"Limited mechanistic follow-up; single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Uncovered a mitotic, cell-cycle-coupled regulation of BCL9 in which CDK1 phosphorylation at Thr172 limits clathrin-mediated LRP6 degradation to sustain mitotic Wnt signaling.\",\n      \"evidence\": \"Mitotic interactome MS, Co-IP, T172A phospho-mutant, cell division assays\",\n      \"pmids\": [\"30217955\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct BCL9\\u2013clathrin contact and stoichiometry not fully defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated tissue-selective \\u03b2-catenin cofactor function by showing the \\u03b2-catenin\\u2013BCL9\\u2013Pygo complex is specifically required for cardiac developmental Wnt programs while other Wnt responses persist.\",\n      \"evidence\": \"Combined Bcl9/Pygo mutants in zebrafish and mouse, cardiac gene expression analysis\",\n      \"pmids\": [\"30366904\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why cardiac targets depend selectively on BCL9/Pygo unresolved\", \"Direct chromatin targets not enumerated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed genetically that BCL9/Bcl9l are required for \\u03b2-catenin-driven intestinal and hepatic transformation and cooperate with Pygo to shift gene expression from stem-cell-like to secretory differentiation.\",\n      \"evidence\": \"ApcMin/Apc1322T conditional knockouts, genetic synergy with Pygo deletion, expression profiling\",\n      \"pmids\": [\"30760720\", \"30760710\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking BCL9/Pygo loss to Notch-driven differentiation not detailed\", \"Selectivity over normal homeostatic Wnt incompletely explained\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified a \\u03b2-catenin-independent function for BCL9 in stabilizing calcium-signaling and neural mRNAs via paraspeckle proteins under calcium/stress signaling.\",\n      \"evidence\": \"Co-IP with paraspeckle proteins, RNA-IP, live-cell calcium imaging, siRNA in colorectal cancer cells\",\n      \"pmids\": [\"31911584\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct RNA-binding versus indirect recruitment not distinguished\", \"Single lab; novel mechanism not independently replicated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extended BCL9's transcriptional partnerships beyond \\u03b2-catenin by showing it co-occupies enhancers with phospho-S727 STAT3 to drive invasive DCIS target genes.\",\n      \"evidence\": \"ChIP-exo, RNA-seq, BCL9 siRNA in a PDX DCIS MIND model\",\n      \"pmids\": [\"32352029\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct BCL9\\u2013STAT3 binding versus co-recruitment unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolved how BCL9-Pygo integrates into the enhanceosome core, showing a single LDB1-SSBP2 complex binds two Pygo NPF motifs in a deep groove and that LDB/Pygo loss impairs Wnt transcription.\",\n      \"evidence\": \"X-ray crystallography of Pygo2/LDB1/SSBP2, Co-IP, CRISPR knockouts with reporter assays\",\n      \"pmids\": [\"37349336\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and architecture of the full BCL9-containing enhanceosome not resolved\", \"Dynamics of the Wnt-triggered rearrangement not captured structurally\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Reported a BCL9\\u2013Nrf2 interaction that modulates ferroptosis susceptibility in thyroid carcinoma, extending BCL9 into redox/cell-death control.\",\n      \"evidence\": \"Co-IP, siRNA knockdown, ferroptosis assays, xenograft model\",\n      \"pmids\": [\"39291848\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single Co-IP from one lab; interaction not independently replicated\", \"Direct versus indirect effect on Nrf2 stability not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BCL9 achieves context- and tissue-selective Wnt target gene activation\\u2014and how its \\u03b2-catenin-independent RNA-stabilizing, mitotic, and redox functions are integrated\\u2014remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of the complete BCL9-containing enhanceosome on chromatin\", \"Molecular determinant of program selectivity unknown\", \"Relationship among the distinct \\u03b2-catenin-independent activities uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 12]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [6, 12, 21]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 8, 12]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [2, 21]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 12]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [6, 12, 18]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [8, 9, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 16]}\n    ],\n    \"complexes\": [\"Wnt enhanceosome\", \"\\u03b2-catenin/BCL9/TCF complex\", \"Pygo-BCL9-LDB1-SSBP core complex\"],\n    \"partners\": [\"CTNNB1\", \"PYGO2\", \"TCF7L2\", \"LDB1\", \"SSBP2\", \"TLE\", \"STAT3\", \"NFE2L2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}